-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VmSEKb1zANjOGTzKqVnGAbCIdZ8LNJsKsWOF1qUgPK/cg+PCVc2n7+vcJ24gvVIJ xa+AxU+EbVbHfouw7LzIZA== 0001104659-05-035673.txt : 20050802 0001104659-05-035673.hdr.sgml : 20050802 20050802160044 ACCESSION NUMBER: 0001104659-05-035673 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20050728 ITEM INFORMATION: Changes in Registrant.s Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050802 DATE AS OF CHANGE: 20050802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: POWER 3 MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0001063530 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 650565144 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24921 FILM NUMBER: 05992057 BUSINESS ADDRESS: STREET 1: 8374 MARKET STREET STREET 2: SUITE 439 CITY: BRADENTON STATE: FL ZIP: 34202 BUSINESS PHONE: 9413603039 MAIL ADDRESS: STREET 1: 8374 MARKET STREET STREET 2: SUITE 439 CITY: BRADENTON STATE: FL ZIP: 34202 FORMER COMPANY: FORMER CONFORMED NAME: SURGICAL SAFETY PRODUCTS INC DATE OF NAME CHANGE: 19980924 8-K 1 a05-14090_18k.htm 8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 28, 2005

 

Power3 Medical Products, Inc.

(Exact name of registrant as specified in its charter)

 

New York

 

0-24921

 

65-0565144

(State or other jurisdiction of
incorporation
or organization)

 

(Commission File Number)

 

(I.R.S. Employer Identification
No.)

 

3400 Research Forest Drive, Suite B2-3
The Woodlands, Texas  77381

(Address of principal executive offices and zip code)

 

(281) 466-1600

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 4.01.                                          Changes in Registrant’s Certifying Accountant.

 

On July 28, 2005, the management of Power3 Medical Products, Inc. (“the Company”) decided upon a change in its independent public accounting firm and confirmed that the Company would no longer engage Kingery & Crouse, P.A. as its independent public accounting firm.  On that same date, the Company engaged the services of John A. Braden & Company, PC, as its independent public accounting firm for its fiscal year ending December 31, 2004.  The Company’s Board of Directors authorized the engagement of John A. Braden & Company, PC as the Company’s independent public accounting firm.

 

The audit report of Kingery & Crouse on the Company’s financial statements as of and for the fiscal year ended December 31, 2003 did not contain any adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, but did contain modifications as to the Registrant’s ability to continue as a going concern.  From the date of Kingery & Crouse’s appointment through the date of their dismissal on July 28, 2005, there were no disagreements between the Company and Kingery & Crouse, P.A. on any matter listed under Item 304, Section (a) (1) (iv) A to E of Regulation S-B, including accounting principles or practices, financial statement disclosure or auditing scope or procedure which, if not resolved to the satisfaction of Kingery & Crouse, P.A. would have caused them to make reference to the matter in its reports on the Company’s financial statements.  A letter from Kingery & Crouse is attached hereto as Exhibit 16.1, indicating whether it agrees with the statements herein.

 

The Company has engaged John A. Braden & Company to audit the Company’s financial statements for the year ended December 31, 2004.  The Company’s fiscal 2004 financials have not been filed in a 10-KSB for 2004 and Kingery & Crouse did not report on the financial statements of the Company for the fiscal year ended December 31, 2004.

 

In deciding to select John A. Braden & Company, the Board of Directors of Power3 reviewed auditor independence issues and existing commercial relationships with John A. Braden & Company and concluded that John A. Braden & Company has no commercial relationship with the Company that would impair its independence.

 

During the two most recent fiscal years ended December 31, 2003 and December 31, 2004, and the subsequent interim period through June 28, 2005, the Company did not consult with John A. Braden & Company, PC, regarding any of the matters or events set forth in Item 304(a)(2)(i) and (ii) of Regulation S-K.

 

Item 9.01                                             Financial Statements and Exhibits

 

(c)                                  Exhibits

 

Exhibit Number

 

Description

 

 

 

Exhibit 16.1*

 

Letter from Kingery & Crouse P.A. regarding agreement with 8-K statements

 

2



 

Filed herewith

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Power3 Medical Products, Inc.

 

 

 

 

 

 

By:

/s/ Steven B.Rash

 

 

President & Chief Executive Officer

 

 

 

Date: August 2, 2005

 

 

 

3


EX-16.1 2 a05-14090_1ex16d1.htm EX-16.1

Exhibit 16.1

 

 

 

July 28, 2005

 

Securities and Exchange Commission
450 5th Street, N.W.
Washington, D.C. 20549

 

Re:  Power3 Medical Products, Inc..

 

Dear Sirs/Madams:

 

We have read the statements in Item 4.01 of the Current Report on Form 8-K of Power3 Medical Products, Inc. dated July 28, 2005.  We agree with the statements concerning our firm in such Form 8-K.

 

Yours truly,

 

 

Kingery & Crouse, P.A.

 

 

2801 WEST BUSCH BOULEVARD, SUITE 200, TAMPA, FLORIDA 33618

PHONE: 813.874.1280    FAX: 813.874.1292    WWW.TAMPACPA.COM

 


GRAPHIC 3 g140901kii001.gif GRAPHIC begin 644 g140901kii001.gif M1TE&.#=A0P%:`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P` M````0P%:`(<```![>WNK($*`@````("``(``@(#`P,#`W,"FRO`$!`0("`@, M#`P1$1$6%A8<'!PB(B(I*2E5555-34U"0D(Y.3G_?(#_4%#6`)/,[/_OUL;G MY]:MJ9`S``!F``"9``#,````,P`S,P!F,P"9,P#,,P#_,P``9@`S9@!F9@"9 M9@#,9@#_9@``F0`SF0!FF0"9F0#,F0#_F0``S``SS`!FS`"9S`#,S`#_S`!F M_P"9_P#,_P```#,S`#-F`#.9`#/,`#/_`#,`,S,S,S-F,S.9,S/,,S/_,S,` M9C,S9C-F9C.99C/,9C/_9C,`F3,SF3-FF3.9F3/,F3/_F3,`S#,SS#-FS#.9 MS#/,S#/_S#,S_S-F_S.9_S/,_S/__S,``&8S`&9F`&:9`&;,`&;_`&8`,V8S M,V9F,V:9,V;,,V;_,V8`9F8S9F9F9F:99F;,9F8`F68SF69FF6:9F6;,F6;_ MF68`S&8SS&:9S&;,S&;_S&8`_V8S_V:9_V;,_V;_`,S,`/\`F9F9,YF9`)G, M`)D``)DS,YEF`)G,,YG_`)D`9IDS9IEF,YF99IG,9IG_,YDSF9EFF9F9F9G, MF9G_F9D`S)DSS)EFS&:9S)G,S)G_S)D`_YDS_YEFS)F9_YG,_YG__YD``,PS M`)EF`,R9`,S,`,P`,YDS,\QF,\R9,\S,,\S_,\P`9LPS9LQF9IF99LS,9LS_ M9ID`F&AH:6 MEI;+R\NRLK+7U]?=W=WCX^/JZNKQ\?'X^/C_^_"@H*2`@(#_````_P#__P`` M`/__`/\`______\(_P#_"1Q(L*#!@P@3*ES(L*'#AQ`C2NSUKY3#HX"X$1) M$@W#H&D^_%C*M`B:GP/1O(%:,6;/DB^M9BU*4^`DH5NQYE0YB>K`H%>'/F5Y M<^N;D`]_I"F21BY=NW7GYKVK%Z_?NI+:!!XLN##APX83'T989*F1'X\?_RAR M,`V0R7(A0TXC\(WFR)I_&/WG6'/=MPL_@*XK6:$MUJ%_7"YMI&NORP<_-`;] M>/=GS+PY#YRDN3'LWK\EKRVHVC3F'UT)>DX.^0-\O3OW[]N-M/\9 M'YC\^,+FTZ-?7[X-0IDI>Q=UQ-*D&Z92W=`<:1)-XY@S"92?(S\(4)U9!/$2 M4Q'_P33:08TQY4AT__#24E,#+<5+0=Z\(95_9-9&K8P1.!C`BW5 M96UQ&8&B09#1MU`O13P&!(*0A9G0BS\$"=%23RI9A)$%-AJIDI-""H1@6F9* MI22:4LFE0L8U%&&<"A'W`X(9%D'24H8:]$9C"O7_HAMT#[EIYU*H5LAJ7"2-9F4!- M1BI"2]'GV+&0>>-K9NI&!!FB71;1ZD$A)B17L@LA>]!E^)K)IK+854KIP-(Z M*ZF1XF'):1O7=OII0HT]>!`O3(&;D*D6,_>#&_],-^]`TR6DFW4:Z69@Q@-1 M3&O`>R:X:UQ%D%P0@3)?_#+`RR;YI,X&0^ESDE(RW/#0GN;,[<21/32F$2@/ M])B?F0D+&8)WY7H4M%VF\7%!F]EK1+\*K6D$H6E(3&^:.`LI,*0&+LESI8\V MFO"6U1*MY<.,R860+><^_V2JU9!Q7-%2+;L:,TOE=@1CKBIO+9U^ZP(+T22- M(?CKO&@847/:"C$[Z=IMQ]VVDGNU';3=0V>[T+8L72::KD$P M>C0)G9WC"5*?$"T];D&>&1$YV)SS"3JDHB-\L*-*BBTHD08 M*Z04BBJ_?E#(8DY6>$8R)M0X2"HCC]!TJ*Z/N[')9[WD\D;R['.S4E+?L/5\ M0MM`''&FC"RM:0)Y&D'24)=<$6=LQ.-=\@H5$N`])'<7D^!9*%B_+D6J+E'J MV<#6=BG_70N`!0G50$SDOGSAJG-%$-Q`FI,01\"*:WI+GOP\\JL6ZLA\'C0; M9O\ZF+,E-:]G^M,9T*9D0DVI#E1&.%H:'N.X,K#UP-;](?\AZFP"+`==L21")D$C-#(D+IP2V7GRN:/I"G;)!PQ MDJ^:!L%M#<5K#1(0Q3=[R;MNSRPH[\K7>%3!4EI7,X M@MB06#HL38S6^8%;F+%`$5IG:=(P%8F\ZE2)>Z:]D-3_)!"*;E+-4R+IB$3* M;.)16\=IY=6N*#NP+:UP723(`Q7Z.SWU@A>]L$5&-XI1B@;3)21)B50B]!BM MH2\OX]0G-)_7F"9!!GH]DUX3IW?0A9240$MA9$2Z)[)>54:-TDDD3CWZR)L5 M=64'\<;NE(+.AU!,6Q!()D:><8HGH&7[_X/.BM[9/W MNRIA-Z6M*`Y'0AH9$T/[VL*H_[W6"%[$3?<4Z.@%XQ>I#+D`Q_(9'R_!&>8\7FT0;Y?8!VU M%\`DN91#ZZZ7$@*:=[Z2T@NN(:[$AB!;F%7'I^D=,"%CX"X'6,,45BFC!`!8 M`[6ZD[UY$F`QNQ2EG.?6=ULS0XYD8M":%W"-Y3'E-A?4$[M+.SA^;U\SV5E" M]QB&3];G5)L4S?QA-W\&S$FY<[\Z"BG2+W26A$WZ2GI MJTO3S'V50)]&-6U+F6,GKTVI(OE:(0#7-82:$IL>_VK5$?J`<##;)*8*AZD% MFN0/QDV[`A$;K$F)$3V-^5:X!VOBNFH*JV,$=\(S:L,X17N,3"R9=0M$5C$R MT`^4,!3'6V?ISW0?[[T MU=/Q?XBC(VX0H-*&^2&A3$*0U0^__Q@;_::_O(DOO-0V8M:OF/9W5_SPC[_\ M'Q*)-M0_,/>W?V'JS__]^S]@O=1SOR&`H-%SE>=&MN!;PG5U]6,+P`5<1"=F M&%46##A__]!YIX0=(`0ET3(M'P,A&EA5H96@+F#4K;\@4C$1\W$%Y#D1Y61'*280MJ`;`I%X MSU%XA'A9'_^`A4&BA=;"*9^W3XN&;9+R;X,A"21X'F5H$.H6165A$-[@".%6 M)Y=&"<(E27017,*E@!,R19F1::`(&J/X8BC58ZLX)V^@@+G2"Z_X5K0T7`Y6 M%]\G2WOQ#YXV&DHU7'WB6ZJH@,$5C<.$8)JT;4=V0EP(8JS&C5UH)&%X@>,! M+KQP'A%Q1FEP@K_B>@B72L#W'OC15V-D17)&$/,55:8B)C1V8)7C>#84C@=G M?,DCB=HH)/T%3Z858JRF$)V8,>7X?AM4%^YT0;!BC05A>X3V(V=#BPKA"+.1 M,6KU$*:84G(1;<'$.F>%6Y9F81TQ'@;E'AL2DQ6"!T$>4+J08!, MT77Z13IV$25%`@0*48(H%!B?:%L9$2BLEC&L,3EY]44"Z1"\D#1I99%^HT&A MYA!XE3UB@V[A8@15"1=7B3J1L#9>2&T*:3!A6!X((1B5>!#^\8@<,2MF,93' M)D,>PQ&FLB=,&6=--1D85B?^Z&]2XWIN-)AV(PX#H>`2\;!)@186Z;1$L0\90IZ9<7=48\;L8\._Q:7YE4FY34Y9G%G\8>:1",'1"8P M=X%MG_25B#E="W&=8BB;.8-O#9$2Z?DO9D1%6V62_0F@(>D0LQ14(<@1G&:! M+NF<`0"=909*D=)JD>*%7M=\8SD>!5$>)P@_.%-O39E9E#-W(#%?--&9"(IP M^M(1_VB!%YA-V4@EJ@E/(+<_GO0SG+2@C5F"*3,8#:%Q.(.1V/%EQ2-&7W:@ M#3&27&.,WG0[\\>>0U.8K2EK%_HDU]9J`*F3%<*3#2&>`&.9GC49,C-$(8%! M*HHNF340WJ`:@<81Z@E_4OH_2%(I1(:CC"9"8LD0'@JD!J$>@2&@0PJ@%U,\ MXQ1F'2&,CV>7"/_ZCFY2%T#`GP?1H%$*:?Y3F*_V:I>X))H*D`(QAB@S!`\Z M'B;"D@]1;QZ2JB,%(W`73D`4$HND2.VHIE3SATYA"\KY'M-2:XWHJ9PS8@$P MIUFBFOM&39LZ+3R:$"48K()4CIRH2!$&,"CE&[Y14O54/GZF.Y4S.,)YG.^8 M,K`Q28Z`A<0A>;^W>-`EK-9"I8MVF-,5-Y/BJ6.(2HP9>*9*;UZE$A-2%'GG M(U0!>:$)<;N2IE*SIHYUAHMH4N^#*QC5L!?E#0U[7^KJ,$F$I_4)*76:B0M! MEB/HIP=AEC3R&!,),&@2*\21EX\GJ""!A"7'J,?RK9&4>*S!9V(#HX/_.9B8 M>C_995T*F5W%&HZ>2"->.EG7Z28:&:(PFT*?AHH$ZA`XM2$$ZT+DJ3XE2J9F M\:(..J-6HK760JS[!5-?*VM@![(#09:52);+='%P0:19\P,CN[0?(8N+VJTB M61<;$11R06Q5MA'3-X;E48D/29OW":%4PJZ/,D?4E9B-O"'&]@LNE*!:P-10@*32Y MA^)KV_,1(`)>@3F>/Z$4\RN:R8*U',%=33.]8CB._)N]7'M'-1J[&WA=1<9/ MOWN!V"O`M.F8$)*TBY*M_\"V4OL3P.D1OCFWB96"XZ1L42ZL1W*4^0[N) M_V"VV4NX$9JX"&P@TGFX=O>Q'*J)Y@A6W_.D=V>43CMY7M2F'`>G.94R(.Q8 MAP2Z$5&R(-.=9`6Q?\JL;G;##/PI`7P0P&I0U=*ZTM255.6ZV6:=CVG%P:H0 MT_&)".&DQ;+`M@05'$9H.1`U:VD+_7[MAQACG,H-,\!9`IU^I9"6Q,C4%3<':!AETHF1 MF\*>*+UBTG@*2U;3H;FR!(R`PD9EL373`8%A8DEJ9RB]\(3HVI'5`2'=9\?4Y44<7*2A[02X*&S0NPW,[Y&=2,S7[L M5U+.`=F2[4OA&MFR,;9]:\@=NAXHLR;5JBHI46^[@3*_LAK/(4@G&QH'(;R? M,85,`29ZB7Q$6&^@02B4-$O&$5+GI!D_T7NF3:W(-WN302$ES)#%'<77"RXE MN(G,[9C-O=S.'=W+#85`V'U1J*K5K:I4^"H;6[HC_TW5'CJ$C`AWLS5GST%X M5K/59"K><8B;#^$9C%AK1WL0'O`!U!S?@]@RBOB'\D1K62>9_XN["($/0SN; M-0RC'V'508)1$^((JMB[`)/6#;Z`'@%<#4X)]YM6E*#;]QH1@+RQ#1R;SXK@ M)%[B)G[B*)[B*K[B+-[B+O[B,/YO@)K9-#[C-LX>-8[C-QY].Y[C/*[C0/[C M0N[C1-[C1A[D18[D1S[D2Y[D3*[D4$Z]I3OE5%[E5G[E6)[E6K[E7-[E7O[E M8![F8C[F9+[EWQWC:)[F:K[F;-[F;O[F)[G`/`P;:#G M>2Z&?H[G91+H?TXC>P[H@?\^$'T.+H0.``1!Z._'"Y#^Z(Z>,@#0;4-`Z."2 MZ0F!YP4QZ0XA"9[^IX3^Z8'^,**NZ93^Z7Q^Z0D"`&62Z:7>H:/.>:YNZ8/> MZ)3NYUPBZ3`Y@K5^@;`ND^"RZ#$IZ4\T@L+>RMU@Z;NKZ`!P`!6BX,+.Z)4N MDY0NO;R0Z=WEZS3R#P`P!(\N[F5[Z-#^ZMT6[`7!Z99.F\JN[@H1[N:^ZM*[ MZ.UNU<&>Z=I.@K4>[N4>U=W`[X5M$/).[HBN\*(>U1U[Z=CN[S#Y MJ0K?[Q=8[!`O[:3^Z8`+ZQ0W[REFGA`WC^P9L?3^SO7_X/.3U?3KOO)T/Q#_#O)/G^K`SO1A?.OJ7O:$ MW_`?_YBR#OJ`G_*2,`11W?(/P_-[3_.L#NBSK^^-?Q"/G^>G/_5) M_[%\/_*&/@3+G>J`WOPACOK@GOQ@O_LQWY@DK_+0G^Z-[MR3_[S=_G MK6[8!U#]VM_\L=[Z>UZ"KN#\]]G^CAGLEO_^@9']OK[]-C2(428(@\V'&*1(,V%$]LL5&BQ)L]_,EDN-#J$J%")&)D>W"@S M8LR6.1>&;/GSH,.(6%EJ?5K4*L*39)-V-?KRWT2C'\T:[=;1+52;/2E:Y&IW BK,>I<\VJ76D4;%C"A0T?1IQ8\6+&C1T_AAQ9\N3$`0$`.S\_ ` end
-----END PRIVACY-ENHANCED MESSAGE-----